Literature DB >> 34271202

Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case.

Bradley A Connor1, Mara Couto-Rodriguez2, Joseph E Barrows2, Morgan Gardner3, Marina Rogova3, Niamh B O'Hara4, Dorottya Nagy-Szakal4.   

Abstract

We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  B.1.617.2; COVID-19; Delta variant; SARS-CoV-2; bamlanivimab/etesevimab; breakthrough; monoclonal antibody therapy; variant of concern

Year:  2021        PMID： 34271202     DOI： 10.1016/j.ijid.2021.07.029

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN： 1201-9712            Impact factor:   3.623


  8 in total

Review 1.  Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review.

Authors:  Shilpa Gopinath; Angela Ishak; Naveen Dhawan; Sujan Poudel; Prakriti Singh Shrestha; Prabhjeet Singh; Emily Xie; Peggy Tahir; Sima Marzaban; Jack Michel; George Michel
Journal:  Trop Med Infect Dis       Date:  2022-05-22

2.  A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.

Authors:  Mengxin Zhang; Ying Liang; Dongsheng Yu; Bang Du; Weyland Cheng; Lifeng Li; Zhidan Yu; Shuying Luo; Yaodong Zhang; Huanmin Wang; Xianwei Zhang; Wancun Zhang
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

3.  Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients.

Authors:  Xufang Deng; Monika Evdokimova; Amornrat O'Brien; Cynthia L Rowe; Nina M Clark; Amanda Harrington; Gail E Reid; Susan L Uprichard; Susan C Baker
Journal:  Viruses       Date:  2021-09-01       Impact factor: 5.048

4.  Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions.

Authors:  Mary Hongying Cheng; James M Krieger; Anupam Banerjee; Yufei Xiang; Burak Kaynak; Yi Shi; Moshe Arditi; Ivet Bahar
Journal:  iScience       Date:  2022-02-17

5.  ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants.

Authors:  Jianxia Ou; Yanan Zhang; Yongmei Wang; Zherui Zhang; Hongping Wei; Junping Yu; Qi Wang; Guifeng Wang; Bo Zhang; Chunhe Wang
Journal:  Signal Transduct Target Ther       Date:  2022-02-09

6.  Vaccination strategy for preventing the spread of SARS-CoV-2 in the limited supply condition: A mathematical modeling study.

Authors:  Yi-Fan Lin; Yuwei Li; Qibin Duan; Hao Lei; Dechao Tian; Shenglan Xiao; Yawen Jiang; Caijun Sun; Xiangjun Du; Yuelong Shu; Huachun Zou
Journal:  J Med Virol       Date:  2022-05-04       Impact factor: 20.693

7.  Genomic diversity of SARS-CoV-2 in Pakistan during the fourth wave of pandemic.

Authors:  Massab Umair; Aamer Ikram; Zaira Rehman; Syed A Haider; Muhammad Ammar; Nazish Badar; Qasim Ali; Muhammad S Rana; Muhammad Salman
Journal:  J Med Virol       Date:  2022-07-04       Impact factor: 20.693

8.  Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant.

Authors:  Gaetano Cicchitto; Lorena Cardillo; Claudio de Martinis; Paola Sabatini; Rosita Marchitiello; Giovanna Abate; Adele Rovetti; Antonietta Cavallera; Camillo Apuzzo; Francesco Ferrigno; Giovanna Fusco
Journal:  Viruses       Date:  2022-03-21       Impact factor: 5.048
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.